Flexible, Simplified, and Scalable Solutions for AAV Viral Vector Production
WEBINAR
The adeno-associated virus (AAV) is the leading viral vector for in vivo gene therapy. Currently, production is labor intensive and expensive because of adherent cell culture processes. The use of stirred-tank bioreactors allows scalable and robust processes to be developed to meet the most demanding needs for high-dose indications that target large organs, e.g. muscle, skin, or blood. High-performing cell culture media is also crucial to ensure consistent supply.
Here, we highlight the development of two suspension-based AAV upstream production platforms and describe simplified cell culture processes to enable an efficient and cost-effective solution for large-scale AAV production.
In this webinar, you will learn about:
- Market insights, overall process considerations & trends for AAV
- High-performing suspension-based AAV upstream production platforms: VirusExpress® and Sf-RVN®
- Simplifying and optimizing your HEK-based suspension cell culture processes with the new Cellvento® 4HEK
Speakers
David Loong, Ph.D.
Merck
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Rain Lee
Merck
Customer Application Consultant
Rain has over 10 years of experience in chemistry, life sciences, and bioprocessing, specializing in upstream applications from cell line development to fed-batch and continuous perfusion. She leads go-to-market strategy for upstream innovations in APeC (Asia Pacific excluding China), blending technical expertise with commercial insight. Rain supports emerging biotech, CDMOs, and large biopharma, building lasting partnerships to drive innovation and growth.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duration:1h
Language:English
Session 1:presented October 25, 2022